<DOC>
	<DOC>NCT01575756</DOC>
	<brief_summary>The purpose of this study is to investigate pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/RiaSTAPTM in patients with congenital fibrinogen deficiency</brief_summary>
	<brief_title>Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap</brief_title>
	<detailed_description />
	<mesh_term>Afibrinogenemia</mesh_term>
	<criteria>Age ≥ 12 years. Documented congenital fibrinogen deficiency (afibrinogenemia). Life expectancy &gt; 6 month. Bleeding disorder other than congenital fibrinogen deficiency. Presence or history of hypersensitivity to study medication. Presence or history of deep vein thrombosis or pulmonary embolism within 1 year prior to enrollment. Presence or history of arterial thrombosis with 1 year prior to enrollment. Hypersensitivity to human plasma products. Acute bleeding. Pregnant or currently breastfeeding women. Suspicion of an antifibrinogen inhibitor as indicated by previous in vivo recovery (if available). Blood or plasma donation in the 3 months prior to enrollment. Human immunodeficiency virus (HIV) positive with a viral load &gt; 200 particles/µl or &gt; 400000 copies/mL. Endstage liver disease. History of oesophageal varicose bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>